On July 31, DexCom rose 6.28% in after-hours trading, trading at $78.07/share, with turnover of $20.80 million. The rally was driven by the company's Q2 earnings report that comprehensively exceeded market expectations.

DexCom reported Q2 adjusted EPS of $0.70, beating the analyst consensus estimate of $0.61 by 14.75% and representing a 45.83% increase from $0.48 in the year-ago period. Revenue came in at $1.308 billion, surpassing the $1.290 billion estimate and rising approximately 12.9% year-over-year from $1.16 billion. The company also raised its full-year revenue guidance to $5.18 billion-$5.25 billion, lifting the lower end from the prior $5.16 billion floor, versus the FactSet consensus of $5.22 billion.

This marks the second consecutive quarter of meaningful earnings beats following Q1 results in which EPS of $0.56 exceeded the $0.47 estimate. RBC Capital Markets has previously noted that CGM National Coverage Determination remains the biggest catalyst, with U.S. CGM penetration at only around 30% of covered lives, suggesting substantial growth runway ahead.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)